CN114028469A - Pharmaceutical composition for nursing female private parts - Google Patents
Pharmaceutical composition for nursing female private parts Download PDFInfo
- Publication number
- CN114028469A CN114028469A CN202111518519.5A CN202111518519A CN114028469A CN 114028469 A CN114028469 A CN 114028469A CN 202111518519 A CN202111518519 A CN 202111518519A CN 114028469 A CN114028469 A CN 114028469A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- skin
- prepared
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 230000000474 nursing effect Effects 0.000 title abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 241000218691 Cupressaceae Species 0.000 claims abstract description 8
- 240000004980 Rheum officinale Species 0.000 claims abstract description 8
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 8
- 206010046914 Vaginal infection Diseases 0.000 claims abstract description 8
- 201000008100 Vaginitis Diseases 0.000 claims abstract description 6
- 208000002003 vulvitis Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 43
- 229940079593 drug Drugs 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 208000008350 Pruritus Vulvae Diseases 0.000 claims description 14
- 206010056530 Vulvovaginal pruritus Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 13
- 229940088597 hormone Drugs 0.000 abstract description 3
- 239000005556 hormone Substances 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 15
- 206010003694 Atrophy Diseases 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 230000037444 atrophy Effects 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000007803 itching Effects 0.000 description 11
- 241000219061 Rheum Species 0.000 description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 206010070834 Sensitisation Diseases 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000007794 irritation Effects 0.000 description 9
- 230000008313 sensitization Effects 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 7
- 238000010926 purge Methods 0.000 description 7
- 210000003905 vulva Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010058679 Skin oedema Diseases 0.000 description 4
- 206010070835 Skin sensitisation Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 231100000370 skin sensitisation Toxicity 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241001313288 Labia Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- 241000224526 Trichomonas Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 201000006669 vulvar dystrophy Diseases 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229940069514 rhubarb preparation Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for nursing female private parts, which is prepared from the following raw materials in parts by weight: 25-35 parts of radix sophorae flavescentis, 25-35 parts of fructus cnidii, 10-20 parts of golden cypress and 10-20 parts of rheum officinale. The composition does not contain hormone, does not cause female dependence, and has good treatment effect on female pudendum itch symptoms caused by vulvitis or vaginitis.
Description
Technical Field
The invention particularly relates to a pharmaceutical composition for female private care.
Background
Pruritus vulvae is a common symptom in gynecological diseases, and the vulva is a particularly sensitive part, so that pruritus can be caused by various gynecological diseases and external stimulation, and people are difficult to sleep and eat and have restless sitting and lying. Pruritus vulvae usually occurs in the clitoris and labia minora, and also in the labia majora, perineum and perianal region.
The causes of vulvar pruritus are common in many ways: first, vulvar inflammation, in which pruritus vulvae mycotic vaginitis is particularly pronounced, other inflammations may also cause pruritus vulvae, like trichomonas vaginitis, bacterial vaginitis, and also pruritus vulvae. Second, the cause of vulvar pruritus is patients with diabetes, and vulvar pruritus can also be manifested. Third, vulvar dystrophy, with its clinical manifestations of vulvar pruritus, vulvar mucosal tissue edema, ulceration, organized dryness, mucosal whitening, etc. The causes of vulvar pruritus are clinically complicated, and the above three causes are most common.
At present, the external lotion for treating pruritus vulvae has various varieties and irregular curative effects, adopts traditional Chinese medicines for clearing heat, promoting diuresis and relieving itching, and is easy to cause discomfort such as dryness of vulvae and the like.
Disclosure of Invention
In order to solve the problems, the invention provides a pharmaceutical composition for nursing female private parts, which is prepared from the following raw materials in parts by weight: 25-35 parts of radix sophorae flavescentis, 25-35 parts of fructus cnidii, 10-20 parts of golden cypress and 10-20 parts of rheum officinale.
Further, the traditional Chinese medicine is prepared from the following raw material medicines in parts by weight:
30 parts of radix sophorae flavescentis, 30 parts of fructus cnidii, 15 parts of golden cypress and 15 parts of rheum officinale.
Furthermore, the traditional Chinese medicine composition is a preparation prepared by taking medicinal powder of raw material medicines, or water or organic solvent extracts of the raw material medicines as active ingredients and adding pharmaceutically acceptable auxiliary materials.
Further, the formulation is an external preparation.
Further, the external preparation is a granule, powder, pill or solution, preferably a solution.
The invention also provides a preparation method of the pharmaceutical composition, which comprises the following steps:
(1) weighing the raw materials according to the proportion;
(2) grinding the raw materials into powder, or extracting with water or organic solvent, and adding pharmaceutically-acceptable adjuvants or auxiliary components.
The invention also provides application of the pharmaceutical composition in preparing a medicament for treating vulvitis and/or vaginitis.
Further, the medicament is a medicament for treating pruritus vulvae.
In the pharmaceutical composition, the radix sophorae flavescentis is cold in nature, enters large intestine and bladder channels, can clear heat, remove dampness, promote urination, dispel wind and kill parasites, has the functions of clearing heat and removing toxicity, can cool blood, purge fire and dispel wind, helps damp-heat and diarrhea, treats dysuresia, especially dysuresia caused by pregnancy, and simultaneously has a certain antihypertensive effect, thereby being a monarch drug;
the fructus cnidii is bitter in nature, pungent, warm and slightly toxic, enters kidney channels, can eliminate dampness and expel wind, kill parasites and relieve itching, warm kidney and strengthen yang, and assist yang and dispel cold, and modern pharmacological research shows that the extract of the fructus cnidii has the action of an androgen-like effect, and water distillate has the effect of inhibiting drug-resistant staphylococcus aureus and pseudomonas aeruginosa and is a ministerial drug;
the phellodendron bark is bitter in taste and cold in nature, enters kidney and bladder channels, and has the effects of clearing heat and drying dampness, purging fire and removing steam, detoxifying and treating sore and the like. Clearing heat and drying dampness: cortex Phellodendri with bitter and cold properties and settlement property, is good at clearing pathogenic heat and dampness, and can be used for treating dysentery due to damp-heat, damp-heat jaundice with dark urine, yellow and turbid leucorrhea with odor and filth due to downward flow of damp-heat, pudendal pruritus, scanty and dark urine with pain, and loempe and edema due to downward flow of damp-heat; purging fire and removing steam: cortex Phellodendri enters kidney meridian, is effective in clearing kidney fire, and has effects of clearing bone-steaming, and can be used for treating hyperactivity of fire due to yin deficiency, hectic fever, nocturnal emission, night sweat, etc.; detoxification and sore treatment: phellodendron bark, cortex Phellodendri, as an adjuvant drug, has the functions of clearing heat and drying dampness, and removing toxicity and healing sore, and can be used for treating pyocutaneous disease, pyogenic infections, skin eczema, pruritus and other symptoms.
The rhubarb, bitter in taste and cold in property, enters stomach, large intestine and liver channels, and has the efficacies of cooling blood and removing toxicity, purging and eliminating accumulation, dispelling blood stasis and stimulating the menstrual flow, clearing heat and purging fire, and promoting diuresis and removing jaundice. Cooling blood and removing toxicity: the rhubarb can treat the damp-heat rash of the intractable skin, is often used for refreshing the orifices and soothing the nerves, can also treat burns and scalds, has the functions of cooling blood and invigorating the blood circulation, and can be used for relieving the symptoms of conjunctival congestion, swollen throat, gum swelling and pain and the like in the aspect of detoxification; purgative accumulation: if the gastrointestinal tract is silted by food, the rhubarb can be used for dosing, the gastrointestinal tract can be opened rapidly, the intestinal obstruction, the pancreatitis and the gastrointestinal tract blockage can be relieved, and the rhubarb has good curative effect on short-time acute diseases; dredging the channels by dredging the blood stasis: the rhubarb can remove the stagnation of solid food in the body, has good stasis removing effect on blood stasis in meridians and viscera, has more remarkable blood activating force after being baked, can play a role in reducing blood fat, and can also be used for treating the amenorrhea symptom of women caused by blood stasis; clearing heat and purging fire: rhubarb can treat symptoms such as excessive internal heat, oral ulcer, tongue fur pain, throat pain and the like, internal heat can be removed by taking the rhubarb preparation, and discomfort symptoms can be quickly relieved, so that the rhubarb has very remarkable effect of clearing heat and purging pathogenic fire; dampness-draining and jaundice-eliminating: herba Artemisiae Scopariae decoction can be optionally administered if there is constipation in jaundice patients, and the main ingredient is radix et rhizoma Rhei, and can be used for relieving and treating jaundice and dark urine
The medicines have the effects of clearing heat, promoting diuresis and relieving itching, and have the effects of treating pruritus vulvae, large leucorrhea amount, fishy smell of leucorrhea and the like caused by damp-heat in lower jiao. The composition has precise and appropriate compatibility and mild drug property, and animal experiments show that the composition has no stimulation to damaged parts of skin. Years of clinical practice proves that the traditional Chinese medicine composition has a remarkable effect of relieving female private discomfort, particularly has the effects of clearing heat, eliminating dampness and relieving itching for pruritus vulvae caused by damp heat, and does not find irritation symptoms such as dryness, allergy and the like in clinical use. The composition does not contain hormone, does not cause female dependence, has good treatment effect on female pudendum itch symptoms caused by vulvitis or vaginitis, and has clinical popularization and application values.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
Example 1 preparation of the medicament of the invention
The formula is as follows: 30g of radix sophorae flavescentis, 30g of fructus cnidii, 15g of cortex phellodendri and 15g of rheum officinale.
The preparation method comprises the following steps: weighing the medicinal materials according to the proportion, mixing, adding water, decocting for two times, each time for 1.5 hours, mixing decoctions, filtering, concentrating the filtrate to about 1000mL, standing, filtering, adding water to 1000mL, stirring, and filling to obtain the traditional Chinese medicine.
Example 2 preparation of the inventive Agents
The formula is as follows: 25g of radix sophorae flavescentis, 25g of fructus cnidii, 10g of cortex phellodendri and 10g of rheum officinale.
The preparation method comprises the following steps: weighing the medicinal materials according to the proportion, mixing, crushing into fine powder, sieving and mixing uniformly to obtain the traditional Chinese medicine.
Example 3 preparation of the inventive Agents
The formula is as follows: 35g of radix sophorae flavescentis, 35g of fructus cnidii, 20g of cortex phellodendri and 20g of rheum officinale.
The preparation method comprises the following steps: weighing the medicinal materials according to the proportion, mixing, adding 60% ethanol, heating and refluxing for two times, each time for 1 hour, mixing the medicinal liquids, filtering, recovering ethanol from the filtrate, adding water to 1000mL, stirring uniformly, filtering, and filling to obtain the traditional Chinese medicine.
The advantageous effects of the present invention are described below by way of test examples.
Test example 1 skin irritation test of rabbits according to the present invention
1. Test method
Taking 12 healthy New Zealand big-ear white rabbits, wherein the weight of the rabbits is 2.0-2.5 kg, and the females are half female and are not pregnant. After adapting to the environment for 1 week, 8 rabbits (each half of male and female) are selected and subjected to formal tests by a homomorphic left-right self-contrast method. The 8 rabbits were randomly divided into intact skin group and damaged skin group, and 4 rabbits per group were housed in cages. Both sides of the dorsal spine were shaved 24 hours before the test with an electric hair clipper. The range of hair removal is 10cm × 10 cm. Before administration, the dehaired skins were examined for damage due to dehairing and intact skin tests were performed on intact animal skins. 4 rabbits were randomly selected to make damaged skin, and the skin with hair removed and disinfected was scratched with a needle in a shape of "#" to the extent of bleeding. Care was taken to ensure that the degree of skin damage was substantially consistent from both the left and right sides.
0.5ml of the solution (wet itch lotion) prepared in example 1 is directly coated on the skin with hair removed on the left side; the right side was coated with an equal amount of physiological saline as a control. The test medicine or normal saline is applied for 4 times every day, the application is continuously carried out for 7 days, and the skin erythema and edema conditions are observed and recorded every day and are scored. After 12 hours from the last administration of the test substance, the remaining test substance was removed with warm water, and the presence or absence of erythema and edema at the applied part was observed at 1, 24, 48, and 72 hours after the removal of the test substance. After stopping the drug, the recovery and time of the above change and whether the applied part has pigmentation, bleeding spot, rough skin or thin skin are observed for one week.
And (4) observing results: the skin reaction was observed under natural light. Skin erythema and edema were scored according to the scoring criteria given in table 1.
TABLE 1 skin irritation response Scoring criteria
And (4) evaluating the results: the mean integral of each group was calculated for each observation time point, then the mean integral of each animal's stimulation per day for the observation period was calculated and the stimulation intensity was evaluated as in table 2.
TABLE 2 evaluation criteria for skin irritation intensity
Score value | Evaluation of |
0~0.49 | Has no irritation |
0.5~2.99 | Mild irritation |
3.0~5.99 | Moderate irritation |
6.0~8.00 | Severe irritation |
2. Test results
The rabbits with the intact skin group were observed 1 hour after each application of the drug and before the application again, and no erythema and edema appeared on the applied part of the wet itching lotion, no obvious pigmentation and bleeding spot appeared on the applied part, and no rough skin or thin skin occurred. The last administration was carried out for 12 hours, and the occurrence of erythema and edema at the coated site was not observed visually at 1, 24, 48 and 72 hours after the removal of the drug. The observation and recording time points of each animal in each group are 0 point, so that the wet itching lotion has no obvious irritation to normal skin. The scoring is shown in Table 3.
TABLE 3 irritation of the Wet itch lotion on intact skin of rabbits
When the rabbits in the damaged skin group are observed 1 hour after being coated with the medicine each time and before being coated again, the wounds of the damaged skin slightly swell in the four days before, and the skin swelling conditions of the rabbits in the control group and the rabbits in the administration group are basically consistent. After several observations, the application part of the lotion for treating damp itch has no erythema and edema, the application part has no obvious pigmentation and bleeding point, and no rough skin or thin skin occurs. At 12 hours after the last administration, erythema and edema were not observed visually at the coated site 1, 24, 48 and 72 hours after the removal of the drug. Therefore, the lotion for treating damp itch is not considered to be significantly irritating to the damaged skin. The scoring is shown in Table 4.
TABLE 4 irritation of the Damp itch lotion on damaged skin of rabbits
Test example 2 the present invention is an active skin allergy test for guinea pigs
1. Test method
40 healthy and non-injured white guinea pigs with half of males and females are taken, and the weight of the white guinea pigs is 250-300 g. After the laboratory is adapted to the environment for 7 days, 30 qualified animals are selected and randomly divided into 3 groups, namely a normal saline control group, a damp itch lotion group and a positive control group. The solution prepared in example 1 (stock solution of lotion for itching wet) was administered to the administration group, and 2, 4-dinitrochlorobenzene (1% for sensitization and 0.1% for excitation) was administered to the positive control group. 1 day before administration, animals in each group were shaved on their backs without damaging the skin, and the area of hair removed was approximately 4cm by 4cm, and gently wiped clean with warm water for testing.
Sensitization and contact: 1ml of the lotion stock solution for treating damp itch is directly applied to the skin with hair removed, and then fixed by two layers of gauze and bandage. The application time was 6 hours. After the application is completed, the test substance is removed and the administration site is cleaned with warm water. Topical administration was performed in the same manner on days 0, 7 and 14, respectively. The normal saline control group is sensitized with 0.9% normal saline, and the positive control group is sensitized with 1% 2, 4-dinitrochlorobenzene by the same method.
And (3) exciting contact: the test substance is applied to the depilation region again 14 days after the last contact, and after about 6 hours, the drug is removed, immediately observed, and the presence or absence of anaphylaxis is observed at 24, 48 and 72 hours. The normal saline control group and the positive control group are contacted and observed by the same method.
And (4) evaluating the results: the mean scores of each group at each time were recorded in Table 5, and the animals were closely observed for the presence of severe systemic anaphylaxis such as asthma, unstable stance or shock. The nature of the allergic reaction of the test substances to the skin and the severity of the allergic reaction were determined according to Table 6.
TABLE 5 Scoring criteria Table for skin allergy degree
TABLE 6 evaluation criteria for skin sensitization
Incidence of sensitization (%) | Evaluation of skin sensitization |
0~10 | No sensitization |
11~30 | Mild sensitization |
31~60 | Moderate sensitization |
61~80 | Severe sensitization |
81~100 | Extreme sensitization |
2. Test results
Within 72 hours after the contact of the animals after the last sensitization of the lotion group, the skin erythema or skin edema phenomenon does not occur in each animal of the damp itch lotion group, and severe systemic anaphylactic reaction such as asthma, unstable standing or shock does not occur in any animal. In the positive control group, the skin of each animal shows more than moderate erythema and edema, and the skin of the animals shows purplish red erythema and/or mild eschar formation in severe cases. Comprehensive evaluation indicates that the evaluation of skin sensitization of the wet itch lotion should be non-allergenic response. The scoring is shown in Table 7.
TABLE 7 Damp itch lotion in Guinea pig active skin allergic reactions
The experimental results show that the animals of the wet and itch lotion administration group do not have skin erythema or skin edema within 72 hours after the contact, and no serious systemic anaphylaxis such as asthma, unstable standing or shock occurs in any animals. It is stated that the active skin sensitization evaluation of the wet itch lotion should be non-allergenic
Test example 3 clinical application
The composition is used as a decoction of an agreement formula as a traditional Chinese medicine research institute of the academy of traditional Chinese medicine science of Sichuan province for more than 5 years, is mainly used for treating diseases such as bacterial vaginitis, colpitis mycotica, atrophic vaginitis, vulvitis, vulvar dystrophy and the like, is used for thousands of people every year, and has obvious curative effect. The statistics for recent use are as follows:
1. data and method
1.1 general data
100 cases of atrophic vaginitis patients in 6 months to 6 months in 2019 of the hospital are selected as the subjects of the study, and the subjects are randomly divided into 2 groups according to a random digital table method, wherein each group comprises 50 cases. The patients in the study group were in the age range of 48-76 years, with the average age of 57.3 years. The age range of the patients in the control group is 50-77 years, and the average age of the patients is 58.7 years. The patients in the 2 groups have no statistical difference (P <0.05) in sex, age range and the like and are comparable.
1.2 drugs and methods of administration:
the control group is treated by Baofukang suppository, female patients in the control group are put into the vagina 1 granule per night, and 7 days is 1 treatment course. The patient is examined in the hospital 3-5 days after stopping taking the medicine. Clinical symptoms completely disappeared, and the course 2 was allowed to follow after 1 month if the patient had been examined (+) under a microscope.
The study group used the solution (wet itch lotion) prepared in example 1 on the basis of the control group, and the specific formulation was as follows: 30g of radix sophorae flavescentis, 30g of fructus cnidii, 15g of raw rhubarb and 15g of golden cypress. 2000mL of water is added into the prescription medicine, and the medicine is filled in a bathtub and used for fumigating and washing vulva for 15-20 min or 15min for hip bath, 2 times a day and continuously treated for 2 weeks.
2. Evaluation indexes are as follows:
the clinical symptoms such as burning pain, pruritus and abnormal secretion are defined to disappear as the cure: the vaginal secretion hypha and spore (-) are detected by a microscope, the vaginal health index score is increased, the vaginal atrophy index score is increased, and the recovery is realized when no relapse occurs within 3 months; the clinical symptoms basically disappear to be obvious effect: microscopic examination (+ -) or (-) is significant, the vaginal health index score is increased or the vaginal atrophy index score is increased; the clinical symptoms are improved to be effective: microscopy (+ -) or (-), increased vaginal health index score or increased vaginal atrophy index score; no improvement or even worsening of clinical symptoms is ineffective: microscopic examination gave no increase in vaginal health index score and no increase in vaginal atrophy index score.
Recurrence was defined as complete disappearance of clinical symptoms, microscopic (-) which reappeared within 3 months, and positive hyphae and spores of vaginal secretion.
The vagina health index consists of 4 parameters, the score of each parameter is 1-5 points, the total score is 20 points, and if the score is high, the vagina health condition is good, and the specific table is shown in table 8.
TABLE 8 vaginal health index score
The vaginal atrophy index score is composed of 6 parameters, the score of each parameter is 1-3, the total score is 18, and if the score is high, the vaginal atrophy degree is light, and the specific table is shown in table 9.
TABLE 9 vaginal atrophy index score
3. The evaluation method comprises the following steps:
the effective rate of treatment of 2 patients and the relapse after treatment of 2 patients were recorded by comparison. Effective rate (cure + significant effect + effective) cases/total cases × 100%.
4. Results
The statistics of the vaginal health index are shown in table 3, and the statistics of the vaginal atrophy index are shown in table 4. Tables 10-11 combined with microscopic examination gave the treatment status of 2 groups of patients, as shown in tables 12-13.
TABLE 102 comparison of vaginal health index scores before and after treatment for patients in groups
TABLE 112 comparison of vaginal atrophy index scores before and after treatment for patients in groups
Comparison of the treatment effectiveness of the patients in Table 122
TABLE 132 comparison of treatment relapse rates in patients
As can be seen from table 12: the clinical treatment effective rate of a patient in a research group is 94.00 percent, which is better than 78.00 percent of that in a control group (P < 0.05); as can be seen from table 13: the relapse rate of the study patients after treatment is lower than that of the control group (P < 0.05).
Test example 4 typical cases
Case 1
Initial diagnosis time: 2019.8.26, Tian Yi in Tan, Nu in, 22 years old, G0P0, sexual life, and tools for contraception. The patients are diagnosed for repeated pruritus vulvae within 3 months, and the gynecological examination is as follows: vulva married, engorgement, vaginal engorgement, increased secretion. Routine examination of leucorrhea: IV, positive for mold. And (3) diagnosis: colpitis mycotica.
And (3) treatment: the damp itching lotion is prepared by decocting 30g of radix sophorae flavescentis, 30g of fructus cnidii, 15g of raw rhubarb, 15g of golden cypress and 3 doses of the radix sophorae flavescentis, decocting 450ml of water in each dose, 1 time a day and 150ml of water each time, and washing vulva. Clotrimazole suppository 0.15g qd vaginal drug delivery X10 days.
The effect is as follows: the time of the return visit: 2019.9.14, after application of the medicine for the upper part of the clinic, the pruritus vulvae disappears, and the leucorrhea routine is rechecked: II, mold negative.
Case 2
Initial diagnosis time: 2020.7.21, wang a certain, woman, 62 years old, G2P1+ 1. The doctor can see the disease for 3 months due to repeated dryness and itching of the vulva, and the gynecological examination is as follows: the vulva is senile, the labia atrophy, the pubic hair is less, the congestion is caused, the vagina atrophy, the vaginal orifice is a transverse finger, the vaginal mucosa is scraped to bleed, the secretion is thin, and the color is yellow. Vaginal health index 9 points, vaginal atrophy index score 10 points, routine examination of white band: IV, trichomonas negative, mold negative. And (3) diagnosis: senile vaginitis.
And (3) treatment: the damp itching lotion is prepared by decocting 30g of radix sophorae flavescentis, 30g of fructus cnidii, 15g of raw rhubarb, 15g of golden cypress and 3 doses of the radix sophorae flavescentis, decocting 450ml of water in each dose, 1 time a day and 150ml of water each time, and washing vulva. Baofukang suppository one qd vagina medicine application X14 days.
The effect is as follows: the time of the return visit: 2020.8.7, after using the medicine for the upper part of the clinic, the pruritus vulvae is obviously improved, the vaginal health index is 12 points, the vaginal atrophy index is 12 points, and the leucorrhea routine is rechecked: II, mold negative, trichomonas negative.
In conclusion, the composition has precise and appropriate compatibility and mild drug property, and animal experiments prove that the composition does not cause the conditions of red and swollen skin, roughness or thin skin and the like and does not stimulate damaged parts of the skin. Years of clinical practice proves that the traditional Chinese medicine composition has a remarkable effect of relieving female private discomfort, particularly has the effects of clearing heat, eliminating dampness and relieving itching for pruritus vulvae caused by damp heat, and does not find irritation symptoms such as dryness, allergy and the like in clinical use. The composition does not contain hormone, does not cause female dependence, and has good treatment effect on female pudendum itch symptoms caused by vulvitis or vaginitis.
Claims (8)
1. A pharmaceutical composition for female private care characterized by: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
25-35 parts of radix sophorae flavescentis, 25-35 parts of fructus cnidii, 10-20 parts of golden cypress and 10-20 parts of rheum officinale.
2. The pharmaceutical composition of claim 1, wherein: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
30 parts of radix sophorae flavescentis, 30 parts of fructus cnidii, 15 parts of golden cypress and 15 parts of rheum officinale.
3. The pharmaceutical composition according to claim 1 or 2, characterized in that: the preparation is prepared by taking medicinal powder of raw material medicines, or water or organic solvent extracts of the raw material medicines as active ingredients and adding pharmaceutically acceptable auxiliary materials.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein: the preparation is an external preparation.
5. The pharmaceutical composition of claim 4, wherein: the external preparation is granules, powder, pills or solution, preferably solution.
6. A process for preparing a pharmaceutical composition according to any one of claims 1 to 5, characterized in that: it comprises the following steps:
(1) weighing the raw material medicines according to the proportion of claim 1;
(2) grinding the raw materials into powder, or extracting with water or organic solvent, and adding pharmaceutically-acceptable adjuvants or auxiliary components.
7. Use of a pharmaceutical composition according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of vulvitis and/or vaginitis.
8. Use according to claim 7, characterized in that: the medicine is used for treating pruritus vulvae.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111518519.5A CN114028469A (en) | 2021-12-13 | 2021-12-13 | Pharmaceutical composition for nursing female private parts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111518519.5A CN114028469A (en) | 2021-12-13 | 2021-12-13 | Pharmaceutical composition for nursing female private parts |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114028469A true CN114028469A (en) | 2022-02-11 |
Family
ID=80146738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111518519.5A Pending CN114028469A (en) | 2021-12-13 | 2021-12-13 | Pharmaceutical composition for nursing female private parts |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114028469A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1530125A (en) * | 2003-03-13 | 2004-09-22 | 哈尔滨欧替药业股份有限公司 | Medicie composition, preparing method and use for preparing gynaecopathia medicine |
-
2021
- 2021-12-13 CN CN202111518519.5A patent/CN114028469A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1530125A (en) * | 2003-03-13 | 2004-09-22 | 哈尔滨欧替药业股份有限公司 | Medicie composition, preparing method and use for preparing gynaecopathia medicine |
Non-Patent Citations (1)
Title |
---|
季成琼: "湿痒洗剂联合保妇康栓治疗萎缩性阴道炎临床观察", 《中国中医药现代远程教育》, vol. 18, no. 15, 31 August 2020 (2020-08-31), pages 76 - 78 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
CN103751663B (en) | A kind of Chinese medicine for external application treating anal eczema and preparation method thereof | |
CN107456509B (en) | A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation | |
US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
CN110613839A (en) | Chinese medicinal biological preparation for acting on female reproductive system and preparation method thereof | |
CN105770239A (en) | External health gel for treating gynecological inflammation | |
CN104274741A (en) | Pharmaceutical composition used for treating gynaecopathia and medicinal sanitary towel | |
CN104721418B (en) | It is a kind of to be used to treat pharmaceutical composition of gynaecological imflammation and preparation method thereof and purposes | |
CN102949662B (en) | External traditional Chinese medicine preparation for treating female reproductive system inflammation and preparation method thereof | |
CN102631589A (en) | Penyanxiao enema and preparation method thereof | |
CN104523853A (en) | Externally applied compound radix arnebiae oil preparation and preparation method thereof | |
CN104306841A (en) | Traditional Chinese medicine lotion for curing gynecologic inflammation, scytitis and pruritus | |
CN110251578A (en) | It is a kind of for koro and the drug of gynaecological imflammation and preparation method thereof | |
CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
CN114028469A (en) | Pharmaceutical composition for nursing female private parts | |
KR101716956B1 (en) | Herbal medicine mixed composition for relaxing and curing of prostate infection and prostatism and manufacturing method thereof | |
CN102145072A (en) | Traditional Chinese medicine composition for treating infantile eczema and dermatitis skin diseases | |
CN112717015A (en) | A Chinese medicinal composition for treating dermatoses, and its preparation method | |
CN104983983A (en) | Traditional Chinese medicine composition for treating gynecological disease and preparation thereof | |
CN112316075B (en) | Transdermal administration traditional Chinese medicine ointment for treating wind pruritus and preparation method thereof | |
CN103948709B (en) | Palace, a kind of Uygur medicine heat seal Meikang suppository and preparation method thereof | |
CN103721191A (en) | Traditional Chinese medicinal enema for treating female chronic pelvic inflammation and preparation method thereof | |
CN109876089B (en) | Hemorrhoid suppository containing flos Chrysanthemi and its preparation method | |
CN108721422B (en) | Pharmaceutical composition for treating mycotic vaginitis and preparation method thereof | |
CN113144054B (en) | Pharmaceutical composition for treating eczema and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220211 |
|
RJ01 | Rejection of invention patent application after publication |